|[June 11, 2014]
Research and Markets: Helicobacter Pylori Infections - Pipeline Review, H1 2014
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/c59crz/helicobacter)
has announced the addition of the "Helicobacter
Pylori Infections - Pipeline Review, H1 2014" report to their
This report provides comprehensive information on the therapeutic
development for Helicobacter Pylori Infections, complete with
comparative analysis at various stages, therapeutics assessment by drug
target, mechanism of action (MoA), route of administration (RoA) and
molecule type, along with latest updates, and featured news and press
releases. It also reviews key players involved in the therapeutic
development for Helicobacter Pylori Infections and special features on
late-stage and discontinued projects.
Drug profiles/records featured in the report undergoes periodic updation
following a stringentset of processes that ensures that all the
profiles are updated with the latest set of information. Additionally,
processes including live news & deals tracking, browser based alert-box
and clinical trials registries tracking ensure that the most recent
developments are captured on a real time basis.
Reasons to buy
Provides strategically significant competitor information, analysis,
and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of
Identify and understand important and diverse types of therapeutics
under development for Helicobacter Pylori Infections
Plan mergers and acquisitions effectively by identifying key players
of the most promising pipeline
Devise corrective measures for pipeline projects by understanding
Helicobacter Pylori Infections pipeline depth and focus of Indication
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope
Takeda Pharmaceutical Company Limited
Affinium Pharmaceuticals, Ltd.
Microbio Co., Ltd.
MerLion Pharmaceuticals Pte Ltd
aRigen Pharmaceuticals, Inc.
Sigmoid Pharma Ltd.
RedHill Biopharma Ltd.
For more information visit http://www.researchandmarkets.com/research/c59crz/helicobacter
[ Back To TMCnet.com's Homepage ]